

This material is an English translation of the press release announced on Sept. 20, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.


Sept. 20, 2023

Notification regarding Skin Care Cosmetics with Microneedle Technology

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President: NAKATOMI Kazuhide; hereinafter "Hisamitsu Pharmaceutical") announces that the development of microneedle cosmetics (hereinafter "The product") applying Hisamitsu's microneedle technology "HalDisc beaute[®]" through a partnership with ALBION Co., Ltd. (Head Office: Chuo-ku, Tokyo; President: Shoichi Kobayashi; hereinafter "ALBION").

The product is scheduled to be released by ALBION on Oct. 17 as a limited edition set*¹ that includes the product.

HalDisc beaute[®] is a technology consisting of Gel Patch containing water and beauty ingredients with a microneedle disc that does not damage the stratum corneum. While containing more beauty ingredients, it has excellent adhesion to the skin and moisture retention properties, and reduces skin irritation and pain during peeling.



HalDisc beaute[®] Schematic diagram

Hisamitsu will continue to work on research and development of cosmetics, drugs, and other products utilizing microneedle technology, and promote the commercialization of microneedle technology as stated in the Seventh Medium-Term Management Policy*². In addition, Hisamitsu will actively engage in partnering with other companies to create new value.

*¹ INFINESSE UPSURGE SOLUTION BN NEEDLE CARE SET

*² The Seventh Medium-Term Management Policy

https://www.hisamitsu.co.jp/ir/pdf/medium_term/7th_slide.pdf

[About ALBION Co., Ltd.]

Location: 1-12-2 Kyobashi, Chuo-ku, Tokyo

Established: March 2, 1956

Capital: 760.98 million yen

Representative: Shoichi Kobayashi, President and Chief Executive Officer